Edwards Lifesciences Corporation
Market Cap
$48.94B
P/E Ratio
46.56
EPS
$1.81
Dividend Yield
0.00%
52-Week Range
$65.94 — $87.89
Volume
3.05M
Avg Volume
4.30M
Beta
0.93
P/E (TTM)
46.56
Forward P/E
28.43
PEG Ratio
-2.11
P/S (TTM)
7.81
P/B (TTM)
4.58
P/FCF
88.09
EV/EBITDA
112.20x
EV/Sales
—
ROE (TTM)
0.10%
ROA (TTM)
0.08%
ROIC
0.04%
Gross Margin
0.78%
Operating Margin
0.27%
Net Margin
0.19%
Debt/Equity
0.07
Current Ratio
3.72
EPS Growth (YoY)
-0.90%
Revenue Growth (YoY)
+0.17%
EPS Growth (3Y)
+0.41%
EPS Growth (5Y)
+0.41%
Sales Growth (3Y)
+0.04%
Sales Growth (5Y)
+0.07%
EPS Est (This Year)
$2.96
EPS Est (Next Year)
$3.32
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$7.28
Hold
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $96.38(14.4% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
587.10M
Float
572.34M
Free Float %
97.49%
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
NYSE
IPO Date
2000-03-27
Employees
15800
CEO
Bernard J. Zovighian
Index Membership
S&P 500
Website
https://www.edwards.com
Edwards Lifesciences Corporation (EW) is a healthcare company in the medical - devices industry listed on the NYSE. With a market capitalization of $48.94B, a P/E ratio of 46.56, EW is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare EW against other stocks using dozens of fundamental and technical filters.
Edwards Lifesciences Corporation (EW) has a trailing twelve-month (TTM) P/E ratio of 46.56. This is above the market average, which may reflect high growth expectations or premium valuation. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Edwards Lifesciences Corporation (EW) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Edwards Lifesciences Corporation (EW) has a market capitalization of $48.94 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Hold" rating on Edwards Lifesciences Corporation (EW) with an average score of 3.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $96.38 implies 14.4% upside from the current price.